We Work For Health

Bringing together stakeholders to preserve America’s leadership in the life sciences

[We Work For Health @weworkforhealth]

A major milestone for American investment: Biopharma companies have now committed more than $500B to expand manufacturing capabilities and strengthen the U.S. supply chain. Explore the latest activity in our U.S. Biopharma Investment Watch: https://t.co/Sv9WukBQJZ

[We Work For Health @weworkforhealth]

China's share of global biopharma R&D quadrupled in the last decade and Chinese innovators received 1.8M patent applications in 2024 – about 3x the U.S. total. The innovation race is accelerating. Read more about why this is a key warning sign for U.S. biopharma leadership: https://t.co/3DDybkPZlK

[We Work For Health @weworkforhealth]

Europe has spent decades learning the hard way what price controls do to innovation. As German policymakers consider doubling down on price setting, companies are scaling back investments in response. https://t.co/jC1xQavlrj

[We Work For Health @weworkforhealth]

Patients should be at the center of drug pricing policy. Not shortcuts that risk access to new medicines. Europe shows why. Read WWFH’s latest blog: https://t.co/8S02D3f2ke

[We Work For Health @weworkforhealth]

Ahead of tomorrow's House Judiciary Subcommittee hearing on medicine and IP, WWFH Executive Director @DLeonard_DC sent a letter to members emphasizing the critical role of strong IP protections in advancing R&D, supporting generic manufacturing and strengthening U.S. economic security.

Read the letter here: https://t.co/glag6QNYFX

[We Work For Health @weworkforhealth]

"If lawmakers strip away patent protections for drug innovators, investors will flee the biopharmaceutical industry." @AdamMossoff explains why Congress should follow the data, not rhetoric, in the drug pricing debate. https://t.co/DI5dQuCwgQ

[We Work For Health @weworkforhealth]

WWFH continues to advocate for policies that protect biopharma innovation, support American jobs and safeguard the development of life-saving cures. To learn more about the issues driving WWFH’s work, visit the website: https://t.co/WRKgs6M9PC

[We Work For Health @weworkforhealth]

According to the @EFPIA, 49% of innovative medicines approved 2021 and 2024 failed to reach patients in Europe, where price controls are widely used.

MFN would import those same price controls to the U.S., along with the limits on new medicines that come with them

https://t.co/3LZyJ079xD

[We Work For Health @weworkforhealth]

Chinese biotech companies are catching up to their American competitors. At the same time, MFN pricing policies threaten to weaken the U.S. biopharma landscape by undermining investment, innovation, and competitiveness. Policymakers still have time to change course. More from Anne Pritchett of @CSIS: https://t.co/uFiGCrfUzT

[We Work For Health @weworkforhealth]

The 2026 Special 301 Report highlights a growing divide between the U.S., China, and the EU on intellectual property and innovation policy, while signaling increased U.S. scrutiny of pricing and reimbursement policies in high-income countries that may undervalue innovation and shift more R&D costs onto American patients. This one-pager explores the key trends shaping the landscape: https://t.co/AexGcbsbSL

[We Work For Health @weworkforhealth]

Only half of U.S.-approved drugs ever reach European patients. That's what government price-setting does to innovation.

Yet policymakers in Germany are trying to go further.

As the U.S. considers MFN, let's not make that same mistake.

More from @DLeonard_DC:

[We Work For Health @weworkforhealth]

Innovation requires significant investment. Average annual R&D spending per new approved drug was $4.59 billion, according to IDEA Pharma's 2026 Global Pharmaceutical Innovation & Invention Index. Misguided policies like MFN could cause this investment to dry up. Learn more about how innovation works: https://t.co/CbYXccSNUc

[We Work For Health @weworkforhealth]

China has already surpassed the U.S. in clinical trial volume and is quickly gaining ground in new drug development.

In a new op-ed WWFH Executive Director @DLeonard_DC explains these warning signs and breaks down what U.S. policymakers must do to get back in the lead.

https://t.co/LQyyoektGo

[We Work For Health @weworkforhealth]

"MFN and similar government price control mandates would not lower patients’ out-of-pocket expenses, nor would they address the true drivers of unaffordable care."

As Congress approaches reconciliation debates, WWFH Executive Director @DLeonard_DC warns against codifying MFN-style policies. Read more: https://t.co/tOtQbdOvp2

[We Work For Health @weworkforhealth]

European life sciences innovation has slowed as policymakers on the continent implemented price controls for prescription drugs. The U.S. risks repeating the same mistakes. Learn more about Europe’s experience here: https://t.co/uMLTcg9ILK

[We Work For Health @weworkforhealth]

America’s biopharma industry has a major impact across the states, supporting jobs, driving economic activity and advancing life-saving cures. Visit the website for a state-by-state breakdown: https://t.co/L54WVAPk3j

[We Work For Health @weworkforhealth]

Research indicates that the IRA’s “pill penalty” is already discouraging investment in cancer drug development, especially in early-stage treatments, where interventions are often most effective. This is yet another example of how price controls can undermine innovation and ultimately harm patients. More here: https://t.co/G733x334Vn

[We Work For Health @weworkforhealth]

WWFH is dedicated to supporting the U.S. life sciences sector and the millions of cures, jobs and innovations it makes possible. Learn more here: https://t.co/gvTeW74Qnm

[We Work For Health @weworkforhealth]

In a recent guest perspective, Henry Hadad of @bmsnews underscores the importance of strong IP protections in preserving global competitiveness and sustaining medical progress. https://t.co/8lnQOGeK1J

[We Work For Health @weworkforhealth]

China is no longer just chasing the U.S. in biopharma – it is closing the gap fast, now initiating roughly 30% of global innovative-drug trials, up from barely 5% a decade ago, with momentum concentrated at the Phase 1 and 2 front end of the medicine pipeline. https://t.co/wrhY6SU4Z3

[We Work For Health @weworkforhealth]

The 2026 Special 301 Report strikes a notably tougher tone on intellectual property enforcement, according to @marclbusch. In a recent @thehill op-ed, he explains what this shift means and why clearer differentiation among countries is critical: https://t.co/Rx96cV4b0g